A recent advancement in high-intensity concentrated ultrasound therapy (HIFU) technology has shown its use as an effective cancer treatment.
A multi-institutional research group from China developed a semi-enclosed, spherical cavity transducer that can produce a focused, standing-wave field with a subwavelength-scale focal region and incredibly high ultrasound intensity.
The spherical cavity transducer appeared to generate tighter focal regions and greater pressure amplitude compared with the traditional concave spherical transducer.
Researchers said the level of intensity created by the brand-new transducer style may cause substantial enhancements in HIFU treatment.
The findings were released in the Journal of Applied Physics.
HIFU is a non-invasive, targeted treatment that makes use of sound waves to remove cancer cells.
HIFU uses an ultrasonic transducer to transform electrical signals into sound waves, then concentrates ultrasound into a little focal region to raise the temperature level to more than 65 degrees Celsius.
Therefore, it eliminates cancer cells while doing so without inducing damage to surrounding tissues.
The technique operates in the exact same manner as focusing sunlight through a lens, which assists eliminate the disease-causing cells.
Ultrasound therapy can be utilized as an alternative to traditional cancer treatments such as chemotherapy and surgical treatment.
Ultrasound therapy sound waves successfully treat cancer in various studies
High-intensity ultrasound therapy proved to be a highly-effective cancer treatment in numerous research studies and clinical trials.
For circumstances, scientists at the University College Hospital in London examined 625 males with prostate cancer and discovered that 93 percent of patients who went through HIFU alone stayed cancer-free at five years following the treatment, without needing surgical treatment or radiotherapy.
Information also revealed that just one to two percent of clients who had HIFU treatment suffered from long-term urinary incontinence, compared with 10 to 20 percent of clients who had surgery.
In addition, only fifteen percent of patients in the HIFU group developed erectile dysfunction compared to 30 to 60 percent of surgical clients.
Research study co-author Tim Dudderidge said about the findings:
“The outcomes of this study are remarkable and have the possibility to change prostate cancer treatment for numerous men in the future.
“It is extremely amazing innovation and these results reveal that in guys identified early by prostate-specific antigen (PSA) blood screening, this targeted therapy could be as reliable as a surgical treatment to eliminate the entire prostate gland or radiotherapy and trigger far less adverse effects.”
The findings existed at a yearly meeting of the European Association of Urology in Munich, Germany.
A British clinical trial moneyed by the Medical Research Council has likewise found that 95 percent of patients who went through HIFU therapy for prostate cancer stayed cancer-free at 12 months following the treatment.
The researchers also found that none of the participants suffered urinary incontinence throughout the follow-up duration.
Another sound wave development to look out for
Researchers at the University of Alberta in Canada have actually established a new strategy that uses concentrated acoustic wave to trigger minute particles known as nanodroplets.
In accordance with the researchers, the new strategy was as precise as utilizing needles in a biopsy.
Engineering professor Roger Zemp said in a statement:
“With a bit of ultrasound energy, nanodroplets phase-change into microbubbles.
“That’s important due to the fact that ultrasound can really oscillate these microbubbles.
“The microbubbles absorb of the ultrasound energy and then act like boxing gloves to punch the growth cells and knock little blisters off.
“That led us to find some genes that were indicative of the aggressiveness of the tumor.
That’s potentially really effective.
“You can get a hereditary characterization of the tumour.
“However, do it relatively non-invasively.”
The findings were published in the journal Cancer Research.